Healthcare / BiotechnologyCanadian Sec
$0.05
+0.00 (+11.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-526791.00 · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$10M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-22.8%
↓Gross Margin
66.3%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-5.8%
FCF / Net income
0.19x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.1M · net income $-617861.0 · FCF $-118201.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.1M | $2.1M | $836193.00 | $43931.00 | — |
| Net Income | $-617861.00 | $-617861.00 | $-2.7M | $-1.6M | $-2.2M |
| EBITDA | $-471012.00 | $-471012.00 | $-1.2M | $-1.3M | $-1.9M |
| EPS | — | — | -0.03 | -0.03 | -0.04 |
| Gross Margin | 66.3% | 66.3% | 70.7% | 58.5% | — |
| Operating Margin | -35.4% | -35.4% | -183.3% | -3610.8% | — |
| Net Margin | -30.1% | -30.1% | -317.8% | -3617.4% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.16 | -0.20 | 0.12 |
| Current Ratio | 2.70 | 2.70 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-118201.00 | $-118201.00 | $-1.4M | $-526791.00 | $-1.3M |
| Returns | |||||
| ROE | -22.8% | -22.8% | -103.4% | 154.1% | -181.5% |
| Valuation | |||||
| P/B | 3.35 | 3.35 | 2.24 | — | 4.24 |
| Growth & Yield | |||||
| Revenue Growth | 145.6% | 145.6% | 1803.4% | — | — |
| EPS Growth | — | — | 0.0% | 25.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → n/d
Residual
-23.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.